Patents by Inventor Stanley C. GILL

Stanley C. GILL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11833149
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: December 5, 2023
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
  • Publication number: 20220133725
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Application
    Filed: January 10, 2022
    Publication date: May 5, 2022
    Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
  • Patent number: 11253520
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: February 22, 2022
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
  • Publication number: 20200230142
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 23, 2020
    Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
  • Patent number: 10583142
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 10, 2020
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
  • Publication number: 20170273982
    Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
    Type: Application
    Filed: March 25, 2016
    Publication date: September 28, 2017
    Inventors: Stanley C. GILL, Kenneth K. IWATA, Gregory J. RIELY, Jun WU, Helena YU